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If one relies exclusively on government-funded clinical trial results from the UnitedStates, a misleading message seems to emerge: relatively speaking, few geriatric
Americans are dying of lung cancer. For example, in an effort to define the optimal
chemotherapy regimen for metastatic non-small cell lung cancer, the Eastern Cooperative
Oncology Group 1594 study evaluated 1139 patients, of whom fewer than 20% were 70
years of age or older.1,2 In reality—and as we all know—the opposite is the case: lung
cancer is the leading cause of cancer-related death in the United States; it is a geriatric
malignancy, and modern demographics show that a large cohort of aging Americans is at
risk.3 By 2050, the number of newly diagnosed patients with lung cancer who are 85 years
of age or older in the United States will have quadrupled.4
Why do nationally funded clinical trials from the United States fall short of revealing the
true extent of this malignancy in the elderly? As suggested above, one reason is that few older
patients are enrolled in cancer clinical trials. Hutchins and others observed that patients who
were 65 years of age or older accounted for only 25% of trial participants within the Southwest
Oncology Group, but they accounted for 63% of the United States population with cancer
during this same time frame.5 Admittedly, this discrepancy may be waning, particularly with
the removal of an upper age limit from all government-funded trials, but an updated analysis
that demonstrates age-based parity remains to be seen.
The second reason hinges on the observation that few prospective, nationally funded
trials focus on the elderly. The clinical trial database (PDQ) from the National Cancer Institute
(NCI) reveals that, among more than 400 non-small cell lung cancer trials, only four focus
exclusively on geriatric patients,6 and, as best as this author can tell, none of these is
government-funded. However, when such prospective trials of older patients with cancer have
been completed within the United States cancer cooperative group infrastructure, they seem to
have provided seemingly comparable clinical outcomes for older patients with cancer in
exchange for a more favorable side effect profile.7 Of note, they have also succeeded in
accruing patients who might not have otherwise participated in an age-unrestricted cancer
clinical trial, and they have provided much-sought information on patients 80 years of age or
older, the so-called “oldest of the old.”7 Although there is clear justification for conducting
clinical trials that focus exclusively on the elderly, few are being performed.
Thus, in this context, the article by Altundag et al. in this issue of the Journal of Thoracic
Oncology is timely and important.8 Spanning the years 1997 through 2004 and including 140
advanced, chemotherapy-naı¨ve patients with non-small cell lung cancer aged 80 years or older,
this retrospective study is perhaps the largest ever to describe outcomes in such a group. By
means of a matched case-control design, this study suggests that select patients who are among
the oldest of the old can tolerate chemotherapy. Although many patients who were 80 years
of age or older did not receive platinum doublets, this study reports similar clinical outcomes
based on tumor response rate, tumor progression-free survival, and overall survival among
older and younger patients with chemotherapy. The retrospective design of this study carries
with it inherent limitations, such as the inclusion of only a highly selective group of patients
within a tertiary care center and potentially less detail about adverse events and other clinical
outcomes, but the authors do provide a balanced discussion of their findings. Hence, this study
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fills a void in the literature and provides much needed clinical
outcome data that lend guidance on how to manage the oldest of
the old with non-small cell lung cancer. This report should be
viewed as a major contribution.
Studies such as those by Altundag et al. show that we are
very slowly making progress in the arduous task of defining how
best to treat geriatric patients with lung cancer.8 Powerful pro-
spective trials from Europe have suggested that chemotherapy
improves survival among elderly patients with non-small cell
lung cancer and have shown that the administration of single-
agent chemotherapy can be justified.9,10 However, given the
ostensible paucity of prospective clinical trials among older
patients with lung cancer and the presumed challenges of initi-
ating them in a United States cancer cooperative group setting,
Altundag et al. should be duly commended for providing invalu-
able information—albeit retrospective—that directly affects our
treatment of elderly patients with lung cancer and, more specif-
ically, directly affects our treatment of the oldest of the old.
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